糖皮质激素治疗重症急性胰腺炎的研究进展

Research Progress in Glucocorticoid Treatment for Severe Acute Pancreatitis

重症急性胰腺炎(SAP)是消化系统疾病中的常见危急重症之一,其发生发展与机体炎症反应密切相关。在内科综合治疗基础上,有效抑制SAP患者机体炎症反应起重要作用。糖皮质激素(GC)常用于危重患者,但其对SAP的治疗作用一直存在争议。临床上,因GC存在许多不良反应,其使用会降低机体免疫力、加重感染、引发脓毒症,加重病情,所以一直慎用于SAP治疗。但GC能拮抗SAP炎症反应、抑制全身炎症反应综合征的发生发展,从而改善SAP的预后,故引起广泛关注。未来,需进一步深入研究并证实GC治疗SAP的最佳剂量及时机,为临床使用提供充分依据。

Severe acute pancreatitis(SAP)is one of the most serious digestive diseases,and its development is closely related to the body′s inflammatory response.Based on comprehensive medical treatment,effective inhibition of the inflammatory response plays a vital role in SAP patients.Glucocorticoids(GC)are commonly used in serious illness patient,but the therapeutic effect of GC on SAP has been controversial.In clinical,because GC has many adverse reactions,such as redu-cing the body′s immunity,aggravating infection,causing sepsis and aggravating the condition,it has been used cautiously in the treatment of SAP.However,GC can antagonize the inflammatory response of SAP,inhibit the occurrence and development of systemic inflammatory response syndrome,thereby improve the prognosis of SAP,therefore has aroused widespread concern.In the future,it is necessary to further study and confirm the optimal dose and timing of GC in the treatment of SAP in order to provide sufficient evidence for the clinical use.